全球领先疫苗，39支疫苗进入3期实验，10月13日，德国法国放弃两款mRNA疫苗，转为研发新一代疫苗和加强剂。中国两款疫苗进入第三期试验。
- 主题发起人 lindamy
- 开始时间
- 注册
- 2005-11-23
- 消息
- 30,386
- 荣誉分数
- 7,481
- 声望点数
- 373
加拿大网站更新，进入三期试验的疫苗从15个增加的22个。
新近进入三期试验的疫苗有：
1. Institute of Medical Biology, Chinese Academy of Medical Sciences 中国医学科学院 北京协和医学院 医药生物技术研究所的灭活疫苗；
2. Research Institute for Biological Safety Problems 哈萨克斯坦 的灭活疫苗；
3. Osaka University/AnGes/Takara Bio 日本大阪大学/美国加州Takara Bio等DNA疫苗；
4. Cadila Healthcare 印度卡迪拉医疗保健公司的DNA疫苗；
5. Clover Inc./GSK/Dynavax 中国成都三叶草生物制药公司/英国伦敦GSK/美国加州Dynavax 公司的Protein subunit疫苗；
6. Medigen Vaccine Biologics 台湾高端疫苗生物制剂股份有限公司 Protein subunit疫苗；
7. COVAXX 美国纽约的COVAXX 公司 的 Protein subunit疫苗。
最后编辑:
以色列接种疫苗数据显示，辉瑞疫苗有效率高达99%-综合新闻-蒙城华人网-蒙特利尔第一中文网!
在以色列接种两剂新冠疫苗（由美国辉瑞与德国BioNTech开发）的人群当中，仅有0.01％的人在之后的检测中结果呈阳性。以色列大型非盈利医保机构马卡比（Maccabi）于当地时间1月25日公布了速报数据。
www.sinoquebec.com
- 注册
- 2005-11-23
- 消息
- 30,386
- 荣誉分数
- 7,481
- 声望点数
- 373
以色列已经打了49.1%，马上就过半了，可惜仍未见明显成效。以色列接种疫苗数据显示，辉瑞疫苗有效率高达99%-综合新闻-蒙城华人网-蒙特利尔第一中文网!
在以色列接种两剂新冠疫苗（由美国辉瑞与德国BioNTech开发）的人群当中，仅有0.01％的人在之后的检测中结果呈阳性。以色列大型非盈利医保机构马卡比（Maccabi）于当地时间1月25日公布了速报数据。www.sinoquebec.com
浏览附件955550
- 注册
- 2012-09-04
- 消息
- 62,779
- 荣誉分数
- 11,291
- 声望点数
- 1,373
- 注册
- 2005-11-23
- 消息
- 30,386
- 荣誉分数
- 7,481
- 声望点数
- 373
32 min ago
A Phase 3 trial of biotechnology company Novavax’s Covid-19 vaccine shows it has an efficacy of 89.3%, the company announced on Thursday.
But the company highlighted the vaccine’s apparent efficacy against new variants of the virus that have alarmed politicians and scientists alike.
The trial, conducted in the United Kingdom, included efficacy estimates by strain based on PCR tests performed on strains from 56 Covid-19 cases in the trial. The vaccine was found to have 95.6% efficacy against the original novel coronavirus and 85.6% against the variant first identified in the UK, known as B.1.1.7.
The company also announced that a Phase 2b study conducted in South Africa, where another variant was first identified, showed 60% efficacy.
"With today’s results from our UK Phase 3 and South Africa Phase 2b clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2 and 3 trials involving over 20,000 participants," Stanley Erck, Novavax president and CEO, said in the announcement.
The company's vaccine, known as NVX-CoV2373, “is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants,” Erck said. “NVX-CoV2373 has the potential to play an important role in solving this global public health crisis."
Regarding the trial in South Africa, “the 60% reduced risk against COVID-19 illness in vaccinated individuals in South Africans underscores the value of this vaccine to prevent illness from the highly worrisome variant currently circulating in South Africa, and which is spreading globally,” Shabir Maddi, principal investigator in the Novavax Covid-19 vaccine trial in South Africa, said in the announcement.
"This is the first COVID-19 vaccine for which we now have objective evidence that it protects against the variant dominating in South Africa,” Maddi said.
Novavax says UK Phase 3 trial shows its coronavirus vaccine has 89% efficacy
From CNN's Jacqueline HowardA Phase 3 trial of biotechnology company Novavax’s Covid-19 vaccine shows it has an efficacy of 89.3%, the company announced on Thursday.
But the company highlighted the vaccine’s apparent efficacy against new variants of the virus that have alarmed politicians and scientists alike.
The trial, conducted in the United Kingdom, included efficacy estimates by strain based on PCR tests performed on strains from 56 Covid-19 cases in the trial. The vaccine was found to have 95.6% efficacy against the original novel coronavirus and 85.6% against the variant first identified in the UK, known as B.1.1.7.
The company also announced that a Phase 2b study conducted in South Africa, where another variant was first identified, showed 60% efficacy.
"With today’s results from our UK Phase 3 and South Africa Phase 2b clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2 and 3 trials involving over 20,000 participants," Stanley Erck, Novavax president and CEO, said in the announcement.
The company's vaccine, known as NVX-CoV2373, “is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants,” Erck said. “NVX-CoV2373 has the potential to play an important role in solving this global public health crisis."
Regarding the trial in South Africa, “the 60% reduced risk against COVID-19 illness in vaccinated individuals in South Africans underscores the value of this vaccine to prevent illness from the highly worrisome variant currently circulating in South Africa, and which is spreading globally,” Shabir Maddi, principal investigator in the Novavax Covid-19 vaccine trial in South Africa, said in the announcement.
"This is the first COVID-19 vaccine for which we now have objective evidence that it protects against the variant dominating in South Africa,” Maddi said.
- 注册
- 2005-11-23
- 消息
- 30,386
- 荣誉分数
- 7,481
- 声望点数
- 373
42 min ago
Nicholas Kamm/AFP via Getty Images
President Joe Biden is “encouraged” about Johnson & Johnson’s single-shot Covid-19 vaccine news.
Johnson & Johnson’s vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% effective against severe disease. The company plans to submit an application to the US Food and Drug Administration for emergency use authorization for the vaccine next week.
In the meantime, Psaki said, Biden continues to urge Americans to mask up and follow public health guidelines “until it’s their turn to get vaccinated.”
She declined to “get ahead of the experts” who will brief virtually at 11:00 am and will discuss the new vaccine news further.
2 hr 34 min ago
Johnson & Johnson officials praised their vaccine's 85% efficacy against severe Covid-19 during a phone call with reporters on Friday morning. The call was held along with officials from the National Institutes of Health.
"We have really good efficacy, same level of protection, across all age groups, from the very young to the middle age to the very old. We have the same efficacy across race and ethnicity," Mammen said. "This vaccine is for everyone."
Johnson & Johnson’s single-shot Covid-19 vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% effective against severe disease, the company announced Friday.
The vaccine was 72% effective against moderate and severe disease in the US, the company said.
Biden "encouraged" by Johnson & Johnson Covid-19 vaccine news, White House says
From CNN's Betsy Klein
President Joe Biden is “encouraged” about Johnson & Johnson’s single-shot Covid-19 vaccine news.
Johnson & Johnson’s vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% effective against severe disease. The company plans to submit an application to the US Food and Drug Administration for emergency use authorization for the vaccine next week.
In the meantime, Psaki said, Biden continues to urge Americans to mask up and follow public health guidelines “until it’s their turn to get vaccinated.”
She declined to “get ahead of the experts” who will brief virtually at 11:00 am and will discuss the new vaccine news further.
2 hr 34 min ago
Johnson & Johnson official praises company's Covid-19 vaccine: "This vaccine is for everyone"
From CNN's Jacqueline HowardJohnson & Johnson officials praised their vaccine's 85% efficacy against severe Covid-19 during a phone call with reporters on Friday morning. The call was held along with officials from the National Institutes of Health.
"We have really good efficacy, same level of protection, across all age groups, from the very young to the middle age to the very old. We have the same efficacy across race and ethnicity," Mammen said. "This vaccine is for everyone."
Johnson & Johnson’s single-shot Covid-19 vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% effective against severe disease, the company announced Friday.
The vaccine was 72% effective against moderate and severe disease in the US, the company said.
- 注册
- 2005-11-23
- 消息
- 30,386
- 荣誉分数
- 7,481
- 声望点数
- 373
4 hr 43 min ago
Klaus Cichutek, President of the Paul Ehrlich Institute, addresses a press conference in Berlin, Germany, on January 29. Hannibal Hanschke/Pool/AFP/Getty Images
German officials expect the EU's medicines regulator, The European Medicines Agency (EMA) to approve AstraZeneca’s coronavirus vaccine without age restrictions, despite a previous German recommendation that the vaccine should not be given to people over the age of 65.
“The essential bases have been created for a recommendation for approval without age limit,” Klaus Cichutek, the head of Germany's vaccine regulator said during a briefing in Berlin, cautioning that data is weaker on the vaccine’s effects on older age groups.
Cichutek’s remarks come just a day after Germany's vaccine commission said it recommended that the vaccine developed by AstraZeneca and the University of Oxford should not be given to people aged over 65 years old due to insufficient data.
According to Germany’s Interior Ministry, Germany’s own vaccine commission, STIKO, found there is insufficient data on the “effectiveness of the AstraZeneca vaccine in people over 65 years of age.”
While the European Medicines Agency (EMA) is expected to issue its approval without restrictions, this will likely not be the case for the German vaccine commission STIKO.
Spahn added that the AstraZeneca vaccine may not be authorized in Germany for use in people aged over 65, but the government is still aiming to vaccinate all people over the age of 80 by the end of the first quarter of 2021.
So far, Germany has administered the coronavirus vaccines developed by Pfizer/BioNTech and Moderna.
Some background:
As of Friday, according to Germany's health agency the Robert Koch Institute (RKI), 3.5 million coronavirus vaccines have been distributed across the country with 2.4 million vaccinations administered.
But as the EU experiences a vaccine shortfall, Spahn warned Germany too should expect "some weeks" of shortages.
RKI head Lothar Wieler told journalists on Friday that although Germany is “on a good path,” with infection numbers declining, more cases of new coronavirus variants are being confirmed, putting increased pressure on the country’s hospitals.
According to RKI, 14,022 new coronavirus cases have been confirmed in Germany as of Friday, bringing the country’s total number of cases reported since the beginning of the pandemic to 2,192,850.
German officials expect EU approval on AstraZeneca vaccine without age restrictions, despite advice on over 65s
From CNN's Nadine Schmidt and Claudia Otto
German officials expect the EU's medicines regulator, The European Medicines Agency (EMA) to approve AstraZeneca’s coronavirus vaccine without age restrictions, despite a previous German recommendation that the vaccine should not be given to people over the age of 65.
“The essential bases have been created for a recommendation for approval without age limit,” Klaus Cichutek, the head of Germany's vaccine regulator said during a briefing in Berlin, cautioning that data is weaker on the vaccine’s effects on older age groups.
Cichutek’s remarks come just a day after Germany's vaccine commission said it recommended that the vaccine developed by AstraZeneca and the University of Oxford should not be given to people aged over 65 years old due to insufficient data.
According to Germany’s Interior Ministry, Germany’s own vaccine commission, STIKO, found there is insufficient data on the “effectiveness of the AstraZeneca vaccine in people over 65 years of age.”
While the European Medicines Agency (EMA) is expected to issue its approval without restrictions, this will likely not be the case for the German vaccine commission STIKO.
Spahn added that the AstraZeneca vaccine may not be authorized in Germany for use in people aged over 65, but the government is still aiming to vaccinate all people over the age of 80 by the end of the first quarter of 2021.
So far, Germany has administered the coronavirus vaccines developed by Pfizer/BioNTech and Moderna.
Some background:
As of Friday, according to Germany's health agency the Robert Koch Institute (RKI), 3.5 million coronavirus vaccines have been distributed across the country with 2.4 million vaccinations administered.
But as the EU experiences a vaccine shortfall, Spahn warned Germany too should expect "some weeks" of shortages.
RKI head Lothar Wieler told journalists on Friday that although Germany is “on a good path,” with infection numbers declining, more cases of new coronavirus variants are being confirmed, putting increased pressure on the country’s hospitals.
According to RKI, 14,022 new coronavirus cases have been confirmed in Germany as of Friday, bringing the country’s total number of cases reported since the beginning of the pandemic to 2,192,850.
- 注册
- 2005-11-23
- 消息
- 30,386
- 荣誉分数
- 7,481
- 声望点数
- 373
美国65岁的议员接种两针辉瑞疫苗之后确诊感染。议员在1月20日参加总统宣誓就职仪式当天测试阴性，并接种了第二针疫苗。9天以后，1月29日测试阳性。
辉瑞疫苗试验结果表明，95%有效率。这位议员不幸落入5%的范围。但是无症状，疫苗可能起到保护作用，防治病情恶化。现在对于病人是否具有传染性还没有明确的结论。Dr. Marc Siegel: Congressman tests positive after COVID vaccine – here's what this case tells us
Does this represent a vaccine failure?
By Dr. Marc Siegel | Fox NewsRep. Lynch tests positive for coronavirus after receiving both COVID-19 vaccine doses
Dr. Marc Siegel discusses why the congressman may have contracted the virus despite being vaccinated.Rep. Stephen Lynch, D-Mass., has tested positive for coronavirus – after receiving both doses of Pfizer's vaccine.
Lynch is 65 years old. He does not appear to be overweight but his age alone puts him in a group where he is at risk for complications of COVID-19. The Centers for Disease Control and Prevention now recommends that everyone over the age of 65 be a priority to be vaccinated.
Lynch would be in that group even if he weren’t a congressman. It was appropriate for him to receive the Pfizer/BioNTech COVID-19 when he did.
He attended President Biden’s inauguration after a negative COVID test, but on Jan. 29, nine days after receiving the second dose, he tested positive for COVID-19 after being exposed to a staff member in his office who tested positive earlier in the week. Lynch is asymptomatic and is isolating himself.
Does this represent a vaccine failure? Is the congressman in the 5% group that are not successfully immunized against COVID by the Pfizer vaccine? As long as he remains symptom-free the answer is most likely not. He probably picked up the virus from his staffer and it is in his nose, causing a positive test. But the vaccine is protecting him from getting sick, which is what we are hoping it will do.
The question remains how contagious he is. How much virus does he have? This is known as viral load. Is he less likely to transmit the virus to others because of the vaccine? The answer to this isn’t known yet. This exact question is under investigation, but the chances are very likely that the vaccine also decreases transmissibility even in someone like Lynch, who tests positive as a result of exposure.
Keep in mind that in Israel, observational data has shown that in a group of over 715,425 people one week after receiving their second Pfizer shot, only 317 got COVID. Maccabi Healthcare Services in Israel also revealed that out of 163,000 given both shots, only 31 were infected, compared to 6,500 infections among a control group of unvaccinated people.
It is very clear that the shot works, as the controlled trials showed. It also appears from the Israeli data that the MRNA vaccines decrease transmission, but that hasn’t been proven yet, and Lynch is right to quarantine himself.
The purpose of immunization is to one, protect yourself, and two, protect those around you by decreasing spread.
It would appear that both the Pfizer and the Moderna vaccine are highly successful at No. 1, but it is still unproven to what extent they accomplish No. 2. Of course, Lynch having enough virus in his nose because of contact with a COVID positive associate does not in any way confirm that he is contagious, which is exactly the point. The vaccine may decrease viral load to the point where you may still test positive but no longer are as contagious. We also don’t know exactly what test the congressman had, and this could be a false-positive result.
Finally, though Pfizer measured immunity after seven days and Moderna after 14 days, this doesn’t mean that Lynch would automatically be fully immune nine days after receiving the Pfizer vaccine, as this can vary from one person to the next. The exact amount of immunity one gets with the vaccine and how long it takes to get it will be confirmed over time in millions of people as commonly available assays are developed to test neutralizing antibody titres.
In the meantime, we must err on the side of caution and isolate anyone with a positive test even if we think he or she may be immune from COVID. At the same time, a positive test like Lynch’s doesn’t automatically signal a COVID infection the way it did before. Now, in a fully vaccinated individual, it may simply mean you have some virus in your nose. This is a giant step forward in the war against COVID.
Dr. Marc Siegel: Congressman tests positive after COVID vaccine – here's what this case tells us
Rep. Stephen Lynch, D-Mass., has tested positive for coronavirus – after receiving both doses of Pfizer's vaccine.
- 注册
- 2005-11-23
- 消息
- 30,386
- 荣誉分数
- 7,481
- 声望点数
- 373
14 min ago
After criticism last year for an early rollout, Russia’s Sputnik V coronavirus vaccine is 91.6% effective against symptomatic Covid-19 and 100% effective for preventing severe illness, according to an interim analysis of Phase 3 trial data published in the medical journal The Lancet on Tuesday.
The randomized, double-blind, placebo-controlled clinical trial includes data on 19,866 participants, of whom 14,964 received the vaccine and 4,902 received the placebo. There were 78 cases of Covid-19 among the trial participants, and only 16 of them had received the vaccine. The rest received a placebo, which does nothing.
The trial included 2,144 people over the age of 60, and a sub-analysis conducted on this group revealed the vaccine was well tolerated and had a similar efficacy of 91.8%.
Seventy serious adverse events were reported in 68 trial participants, including 45 in the vaccine group and 23 in the placebo group, but none were considered associated with the vaccination, according to the study. Most of the adverse events reported were mild, such as flu-like symptoms and pain at the injection site.
The analysis includes only symptomatic cases of Covid-19, and the authors note more research is needed to understand the vaccine’s efficacy against asymptomatic Covid-19, transmission and how long protection may last.
The vaccine is a two-dose adenoviral vector vaccine, with doses administered 21 days apart. With this type of vaccine, the adenovirus is altered so that it can deliver a piece of genetic material from another pathogen, such as the virus that causes Covid-19. It’s an approach similar to the vaccines developed by AstraZeneca and Johnson & Johnson.
Sputnik V uses two different vectors that are based on a human adenoviruses in separate shots. Researchers from Gamaleya National Research Centre for Epidemiology and Microbiology in Russia write that using a different adenovirus vector for the booster may create a more powerful immune response than using the same vector a second time, by minimizing the risk of immune system resistance.
Sputnik V only needs to be refrigerated and costs $10 per dose, according to the Russian Direct Investment Fund, which funded vaccine production and is responsible for selling it globally.
Some context: The vaccine is already approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, the Palestinian territories, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Guinea, Tunisia and Armenia. Sputnik V has so far been administered to more than 2 million people worldwide.
Russia drew criticism from scientific circles last year, when it announced the world's first approved coronavirus vaccine for public use in August -- before the crucial Phase 3 trials had been completed.
Read the full story here:
RELATED
Russia’s Sputnik V vaccine is 91.6% effective against Covid-19, interim analysis suggests
From CNN Health’s Jessica Firger and Jamie GumbrechtAfter criticism last year for an early rollout, Russia’s Sputnik V coronavirus vaccine is 91.6% effective against symptomatic Covid-19 and 100% effective for preventing severe illness, according to an interim analysis of Phase 3 trial data published in the medical journal The Lancet on Tuesday.
The randomized, double-blind, placebo-controlled clinical trial includes data on 19,866 participants, of whom 14,964 received the vaccine and 4,902 received the placebo. There were 78 cases of Covid-19 among the trial participants, and only 16 of them had received the vaccine. The rest received a placebo, which does nothing.
The trial included 2,144 people over the age of 60, and a sub-analysis conducted on this group revealed the vaccine was well tolerated and had a similar efficacy of 91.8%.
Seventy serious adverse events were reported in 68 trial participants, including 45 in the vaccine group and 23 in the placebo group, but none were considered associated with the vaccination, according to the study. Most of the adverse events reported were mild, such as flu-like symptoms and pain at the injection site.
The analysis includes only symptomatic cases of Covid-19, and the authors note more research is needed to understand the vaccine’s efficacy against asymptomatic Covid-19, transmission and how long protection may last.
The vaccine is a two-dose adenoviral vector vaccine, with doses administered 21 days apart. With this type of vaccine, the adenovirus is altered so that it can deliver a piece of genetic material from another pathogen, such as the virus that causes Covid-19. It’s an approach similar to the vaccines developed by AstraZeneca and Johnson & Johnson.
Sputnik V uses two different vectors that are based on a human adenoviruses in separate shots. Researchers from Gamaleya National Research Centre for Epidemiology and Microbiology in Russia write that using a different adenovirus vector for the booster may create a more powerful immune response than using the same vector a second time, by minimizing the risk of immune system resistance.
Sputnik V only needs to be refrigerated and costs $10 per dose, according to the Russian Direct Investment Fund, which funded vaccine production and is responsible for selling it globally.
Some context: The vaccine is already approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, the Palestinian territories, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Guinea, Tunisia and Armenia. Sputnik V has so far been administered to more than 2 million people worldwide.
Russia drew criticism from scientific circles last year, when it announced the world's first approved coronavirus vaccine for public use in August -- before the crucial Phase 3 trials had been completed.
Read the full story here:
RELATED
Russia's Sputnik V vaccine is 91.6% effective against symptomatic Covid-19, interim trial results suggest
- 注册
- 2005-11-23
- 消息
- 30,386
- 荣誉分数
- 7,481
- 声望点数
- 373
各种新冠疫苗的简介以及临床新情况和治疗更新
Panda at USA
各种新冠疫苗简介以及临床新情况和治疗更新 介绍了辉瑞疫苗，莫德纳疫苗，强生疫苗， 牛津疫苗，Navavax 疫苗， 以及简单介绍了科兴与国药疫苗。 临床新情况介绍 治疗最新更新
- 注册
- 2005-11-23
- 消息
- 30,386
- 荣誉分数
- 7,481
- 声望点数
- 373
大规模疫苗接种pfizer vs Sinopharm
来源: xintian 于 2021-02-02 19:32:48
这个是蛮好的超大人群全民的试验。两个国家正好使用了不同的疫苗。
Israel: pfizer mRNA vaccine, vaccination % 55%
UAE sinopharm vaccine, vaccination % 33%
是目前第一名和第二名接种率都很高55% VS 33%。 很快就就会到达》70%全民接种率。那么国家的感染人数，感染率变化，住院率，死亡率的数据是非常有力的疫苗安全性和有效性的数据。不足是两个国家感染检测的力度，覆盖率，准确性，临床数据，新冠死亡人数的标准肯定是不可能一样的。这样就不是真正的比较。
但是有数据总比没有数据更好。
Vaccine tracker
https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/
vaccine contract tracker
Covid-19 Deals Tracker: More Than (8.57 Billion Doses Reserved Worldwide
UAE covid live update
United Arab Emirates Coronavirus: 313,626 Cases and 878 Deaths - Worldometer
Isael covid live update
Israel Coronavirus: 664,651 Cases and 4,890 Deaths - Worldometer
大规模疫苗接种pfizer vs Sinopharm - xintian发表于 健康养生 - 论坛 | 文学城
bbs.wenxuecity.com
- 注册
- 2005-11-23
- 消息
- 30,386
- 荣誉分数
- 7,481
- 声望点数
- 373
中国加入WHO新冠疫苗计划将提供1000万剂疫苗 主要用于发展中国家急需（更新版）
2021年2月3日3:11 凌晨更新于2 天前（新增更多细节）1 分钟阅读
路透北京2月3日 - 中国外交部新闻发言人汪文斌周三宣布，中国已正式加入世卫组织的“新冠肺炎疫苗实施计划”(COVAX)，应世卫组织方面请求，中方决定向实施计划提供1,000万剂疫苗，主要用于发展中国家急需；三家中国公司已申请加入该计划。
他在外交部新闻例会上并称，世卫组织开始审批中国疫苗紧急使用的授权。中国同世卫组织等发起方保持密切沟通，为把疫苗作为全球公共产品，实现发展中国家的可及性和可负担性而共同努力。
由世界卫生组织（WHO）和GAVI疫苗联盟支持的COVAX计划将于本月开始向中低收入国家推出疫苗，预计今年将提供30亿剂中的20亿剂疫苗。
中国外交部在1月曾表示，中国疫苗研发企业科兴生物SVA.O、国药集团和康希诺生物6185.HK688185.SS已申请加入世卫组织的新冠疫苗计划。汪文斌今日宣布了供应计划，但没有透露细节。
他在周一的发布会上曾指出，中方支持国内企业同国外的合作伙伴开展疫苗联合研发和合作生产，已经向多国临床试验国家出口了国药集团和科兴公司的疫苗。中国支持有关企业向急需获取疫苗、认可中国疫苗、已授权在本国紧急使用中国疫苗的国家出口疫苗。
周二公布的一项少量采样实验室研究显示，包括中国国药在内的两种中企新冠疫苗能够激发免疫力防御南非变种病毒，但保护效果似乎较弱。（完）
发稿 沈燕；审校 屈桂娟/张喜良
Reuters | Breaking International News & Views
Find latest news from every corner of the globe at Reuters.com, your online source for breaking international news coverage.
